Neurofibromatosis 1 Clinical Trial
Official title:
Effects of an Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
Background:
- Studies show that Internet Support Groups (ISGs) can help parents of children with chronic
conditions. Researchers want to find out if ISGs can help parents of a child with the genetic
disorder Neurofibromatosis Type 1 (NF1).
Objective:
- To see if an ISG for parents with a child with NF1 can give the parents more social support
and less anxiety.
Eligibility:
- Adults age 18 and older with a child (age 0 25 years) with NF1.
Design:
- Participants will register for the study on a website hosted by the Children s Tumor
Foundation.
- Participants will complete 5 questionnaires. These will be about their emotional
well-being, their child s health status, and their contact information.
- The ISG will include a Discussion Forum that participants can enter 24 hours a day, 7
days a week. A professional moderator will post questions and discussion topics. The
moderator can also respond to questions. They will be a psychologist, a psychology
associate, or a nurse-practitioner. Each one will be highly experienced at working with
young people with NF1 and their families.
- The ISG also will contain a chat room. Here participants can chat with other users in
real time. The chat room will be open for one 90-minute session per week.
- The ISG will remain open for 8 weeks. Then participants will retake 4 of the
questionnaires from the beginning of the study. They will also complete 1 other
questionnaire about their experiences with the ISG. Information from any messages
participants post on the ISG website will be collected.
- Three months after the ISG closes, participants will complete the questionnaires one
final time.
BACKGROUND:
- The complex symptom profile in NF1 puts children and adolescents with this condition at
risk for a variety of physical, cognitive, and social-emotional difficulties. Thus,
caring for a child with a chronic medical condition such as NF1 can be challenging.
- Over the last two decades, researchers have been examining the use of internet support
groups (ISGs) as a means of connecting individuals with similar conditions, diagnoses,
or challenges to provide emotional and informational support.
- While the benefits of ISGs have been well documented in many studies of medical
patients, very few have examined the use of ISGs in parents of children with chronic
medical conditions. Further, no studies have been conducted on an ISG in parents of a
child with NF1.
OBJECTIVES:
- The primary objective of this pilot study is to assess the effectiveness of an ISG
designed for parents of children with NF1 on a measure of perceived social support.
- Secondary objectives are to assess effects of the ISG on self-efficacy, depression, and
anxiety, and to explore themes and topics discussed in the ISG.
ELIGIBILITY:
Eligible participants must self-report:
- Being greater than or equal to 18 years of age
- Having a child with a diagnosis of NF1 between 0 and 25 years of age
- Living in the same home as the child with NF1
- Having regular access to a computer with internet capability
DESIGN:
- Parents of children with NF1 will be recruited through Dr. Widemann s NF1 patient
database and through the Children s Tumor Foundation s (CTF) NF registry.
- Eligible participants will be emailed a link to access the study website through the CTF
website. Due to the nature of the study, consent will be obtained online.
- After consenting, participants will be administered (electronically) baseline measures
of perceived social support, self-efficacy, depression, and anxiety. After 8 weeks,
participants will complete the measures again via the same website, as well as a
post-study questionnaire assessing their experiences with participation. Measures will
be repeated at 3-months post-intervention.
- Content analyses will be performed to identify themes and needs of the participants
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00352599 -
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
|
Phase 1 | |
Completed |
NCT05005845 -
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
|
Phase 2 | |
Completed |
NCT03531814 -
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
|
N/A | |
Completed |
NCT00846430 -
Medical Treatment of "High-Risk" Neurofibromas
|
Phase 2 | |
Completed |
NCT03433183 -
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
|
Phase 2 | |
Recruiting |
NCT05331105 -
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
|
Phase 2 | |
Completed |
NCT03310996 -
Non-invasive Stimulation in Neurofibromatosis Type 1
|
N/A | |
Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
Recruiting |
NCT04750928 -
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06262113 -
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
|
N/A | |
Active, not recruiting |
NCT04924608 -
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
|
Phase 3 | |
Recruiting |
NCT02544022 -
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
|
||
Recruiting |
NCT04941027 -
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
|
||
Completed |
NCT05196854 -
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
|
N/A | |
Active, not recruiting |
NCT01650142 -
Modifying Genes in Neurofibromatosis 1
|
N/A | |
Completed |
NCT05377008 -
Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT04879160 -
Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
|
||
Recruiting |
NCT05735717 -
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
|
Phase 2 | |
Recruiting |
NCT05849662 -
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
|
Phase 1/Phase 2 |